Microgen Scientific and Production Association (an affiliate of Rostec’s Nacimbio holding company) has completed the development of a combined measles, rubella and parotitis vaccine. Vactrivir will become the first Russian fixed combination against the three dangerous diseases at once.
The vaccine is planned for export and use within the National Calendar of Preventive Immunization for free disease prevention. The innovative product is a live tissue-culture vaccine produced entirely indigenously. After the registration, it will be used for immunization of children aged 12 months and 6 years. The new vaccine is expected to be registered in Russia in 2019.
“Creation of Russian medicinal products to replace the imported ones is a strategic task. However, we are not just creating analogues, but working to improve the drug effectiveness. The vaccinees’ health check-ups show that our development has an antibody production rate of 95-98%,” said Oleg Yevtushenko, Executive Director at Rostec State Corporation.
To date, the domestic vaccines for the prevention of measles, rubella and parotitis are represented by mono-vaccines for the immunization against each disease separately, as well as a combined bi-valent parotitis – rubella vaccine.
